Somatropin and Human Growth Hormone: Recombinant Identity, Evidence, Units, and FDA Product Boundaries

“HGH” does not by itself establish somatropin identity

FDA’s substance registry maps HGH, human growth hormone, recombinant human growth hormone, and somatotropin as names associated with somatropin.[4] That synonym record helps with terminology, but it does not prove what is in a commercial vial.

The current GENOTROPIN label defines its somatropin as recombinant human growth hormone produced in Escherichia coli. It describes a 191-amino-acid protein with an approximate molecular mass of 22,124 daltons and an amino-acid sequence identical to pituitary-origin human growth hormone.[1]

A catalog item labeled “HGH” is not established as somatropin, GENOTROPIN, or another licensed finished product without source, sequence, mass, potency, formulation, and lot records.

This page summarizes identity, measurement, human evidence, safety findings, and current U.S. regulatory records. It does not provide medical advice or instructions for using any substance.

Identity at a glance

A UNII and a synonym do not constitute product approval or lot verification. Somatropin should also not be collapsed with other growth-hormone molecules whose sequences, conjugates, or pharmacology differ.

How mass and biological activity should be separated

Current GENOTROPIN and Purple Book presentation strengths are expressed in milligrams.[1][2] WHO/NIBSC preparation 98/574 is the second International Standard for somatropin and is assigned 1.95 mg of somatropin and related proteins per ampoule.[6]

That standard does not create a universal conversion for every kit marketed in IU. An IU claim is meaningful only in relation to the particular biological-activity method, reference preparation, assigned potency, material, and lot.

An IU-labeled research kit therefore needs:

• a verified somatropin identity and complete sequence;
• the recombinant expression system and purification basis;
• the activity method and reference standard;
• the per-container activity result and uncertainty;
• the corresponding protein or active-moiety mass;
• evidence addressing aggregation and relevant molecular variants.

Neither a 10 IU nor a 24 IU label can be silently converted into mass using an unattributed online formula.

Evidence label: Official identity and standard records for named preparations. F, unresolved for a kit without a public assay/reference and matched mass.

What human evidence exists for named somatropin products?

The current GENOTROPIN label summarizes human studies in defined pediatric growth-failure or short-stature populations and in adults with growth hormone deficiency.[1] The designs, durations, populations, diagnostic criteria, and endpoints differ across the labeled conditions, and some pediatric evidence is open-label.

These findings support only the propositions and populations reflected in the named product’s current label. They do not establish benefit for healthy people, anti-aging, bodybuilding, athletic performance, recovery, fat loss, or generalized wellness. They also do not verify an unrelated material sold as HGH.

Evidence tier: B, Human evidence for named-product, population-specific label propositions. F, unsupported for healthy-person performance claims or transfer to an unverified research kit.

A safety-critical negative finding in acute critical illness

The current GENOTROPIN label reports two placebo-controlled trials involving 522 non-growth-hormone-deficient adults with acute critical illness. Mortality was significantly higher in the pharmacologic somatropin groups than in the placebo groups: 42% versus 19%.[1]

This is a direct human harm signal in the studied population. It does not quantify the risk of a Serum Research item, because that item’s identity and use were not studied. It does show why broad claims based on growth, metabolism, or recovery are scientifically and ethically inappropriate.

Evidence tier: A, Replicated human evidence of harm in the narrowly described critically ill population. It is not a general risk estimate for other populations or materials.

Other important label limitations

The current GENOTROPIN label includes serious restrictions and warnings involving active malignancy, certain acute critical-illness settings, specific Prader-Willi risk states, glucose intolerance and diabetes, intracranial hypertension, fluid retention, and other product-specific safety issues.[1]

Listing those topics here does not provide screening or treatment guidance. It demonstrates that somatropin cannot responsibly be marketed as a generic performance, body-composition, anti-aging, or wellness compound.

Current U.S. FDA and enforcement status

GENOTROPIN is licensed under BLA 020280, and HUMATROPE is licensed under BLA 019640.[2][3] Other somatropin products have their own application records, presentations, manufacturing controls, and current labels.

The cited GENOTROPIN label covers defined pediatric growth disorders and adult growth hormone deficiency; approval is not a general authorization for healthy-person enhancement.[1] FDA’s current Import Alert 66-71 addresses unapproved HGH/somatropin and describes detention and statutory restrictions relevant to unapproved human-growth-hormone products.[5]

A “research use only” statement does not establish:

• that a material is somatropin;
• that it is an FDA-licensed finished product;
• that its IU claim is valid;
• that it is lawful or suitable for a proposed human use;
• that it inherits evidence from GENOTROPIN, HUMATROPE, or another licensed product.

Status checked: August 27, 2026.

Important evidence limitations

• “HGH” is a broad name and cannot replace sequence, source, and intact-mass verification.
• Somatropin is a recombinant protein; expression system, folding, aggregation, truncation, oxidation, deamidation, and host-cell impurities can matter.
• Current licensed product strengths in the cited records are expressed in mass, while catalog IU require their own traceable potency basis.
• Human studies are tied to diagnosed populations, named products, protocols, and endpoints.
• The acute critical-illness mortality finding is a population-specific harm signal, not a universal numerical risk estimate.
• No cited source evaluates the identity, purity, sterility, stability, or performance of a Serum Research kit.

Frequently asked questions

Are HGH and somatropin the same name?

FDA’s GSRS record includes HGH and human growth hormone among somatropin names.[4] At the product level, however, an HGH label does not prove recombinant somatropin identity, sequence, potency, or licensed-product status.

What distinguishes somatropin from other growth-hormone products?

The current GENOTROPIN label describes somatropin as a 191-amino-acid recombinant protein with the human pituitary growth-hormone sequence.[1] Modified, extended-action, fusion, or differently sequenced products are separate molecular and regulatory identities.

Can somatropin IU be converted to milligrams?

Only when the exact preparation, biological assay, reference standard, assigned potency, and matched mass are known. A generic conversion should not be applied to an unidentified kit.

Are all somatropin products FDA-approved?

No. FDA licenses named finished products under specific applications. A substance name, UNII, or “HGH” label is not an approval.

Does approved-product evidence support bodybuilding, anti-aging, recovery, or athletic claims?

No such inference is supported by the cited records. The human evidence summarized here concerns defined diagnosed populations and specific finished products.

What did the acute critical-illness trials find?

The current GENOTROPIN label reports significantly higher mortality with pharmacologic somatropin than placebo in two trials of 522 non-growth-hormone-deficient critically ill adults, 42% versus 19%.[1]

Does this page provide instructions for somatropin use?

No. It intentionally excludes dosing, administration, reconstitution, treatment, monitoring, and self-use guidance.

Related research-library reading

• Why Named-Product FDA Approval Does Not Transfer to Research Materials
• How We Review Evidence
• Quality Testing: What Identity, Assay, and Purity Results Can and Cannot Show
• Certificates and Lot-Specific Records

Do not place product cards or commercial calls to action inside this evidence discussion.

Sources

1. DailyMed: current GENOTROPIN label, recombinant source, sequence, molecular mass, population-specific human evidence, contraindications, warnings, and critical-illness mortality finding.
2. FDA Purple Book: GENOTROPIN, BLA 020280, current license and presentations.
3. FDA Purple Book: HUMATROPE, BLA 019640, current license and presentations.
4. FDA GSRS: somatropin, UNII NQX9KB6PCL, substance identity, HGH synonyms, and approval disclaimer.
5. FDA Import Alert 66-71, current FDA enforcement record concerning unapproved HGH/somatropin.
6. WHO/NIBSC: somatropin International Standard 98/574, current standard instructions and assigned mass.
7. FDA: Approved Drugs, Questions and Answers, product-specific meaning of FDA approval.